세계의 관절내 점성보충 디바이스 시장 규모는 2023년에 40억 8,000만 달러, 2030년까지 64억 3,000만 달러에 달하며, 2024-2030년의 예측 기간에 CAGR로 7.94%의 성장이 전망됩니다. 관절내 점성보충 디바이스에 대한 수요의 증가는 주로 노년 인구의 증가와 골관절염의 유병률 상승, 비외과적 치료에 대한 수요의 증가, 히알루론산 기반 치료법의 개발 진보, 관절내 점성보충에 대한 명확한 상환 정책 등에 기인하고 있습니다.
관절내 점성보충 시장 역학
세계보건기구(WHO)(2022)에 따르면 2019년 전 세계 약 5억 2,800만 명이 골관절염을 앓고 있다고 합니다. 같은 자료에 따르면 골관절염은 1,900만 년의 장애 생존기간(YLDs)에 기여하고 있습니다. 골관절염은 관절내 연골이 닳아 없어지면서 발생하는 극심한 통증, 부종 등의 증상을 동반하는 '마모성 관절염'으로도 알려져 있습니다.
또한 Australian Institute of Health and Welfare(2020) 보고서에 따르면 2017-2018년 호주 국민 11명 중 1명이 골관절염을 앓고 있으며, 그 수는 약 220만 명에 달할 전망입니다.
따라서 이러한 장비가 관절염/ 골관절염 관절(가장 일반적으로 무릎)의 통증과 부종을 줄이는 데 도움이되기 때문에 사람들 사이에서 골관절염이 증가함에 따라 세계 관절내 점성보충 디바이스 시장이 빠르게 성장할 가능성이 높습니다.
노인 인구 증가는 관절내 점성보충 디바이스 시장을 가속화하는 또 다른 요인입니다. 예를 들어 WHO(2022)에 따르면 2030년까지 전 세계 인구 6명 중 1명 이상이 60세 이상이 될 것으로 예상되며, 2050년까지 60세 이상 인구는 약 21억 명에 달할 것으로 예상됩니다(American College of Rheumatology(2021)).에 따르면 골관절염은 노년층에서 많이 발생하며, 40세 이상에서 가장 많이 발생합니다.
2019년 4월, 미국 식품의약국(FDA)은 Fidia Pharma의 일회용 주사기 TRILURON(TM)을 시판 전 승인하여 최대 6개월 동안 골관절염으로 인한 통증을 완화하는 히알루론산 나트륨 프리필드 시린지(Prefilled Sodium Hyaluron(TM))를 승인했습니다. 이러한 제품 허가 확대는 세계 관절내 대체요법 시장을 촉진할 것으로 예상됩니다.
그러나 히알루론산 치료와 관련된 높은 비용과 관절내 치환술의 효율성 부족과 같은 특정 요인들이 관절내 점성보충 디바이스 시장의 성장에 걸림돌이 될 것으로 예상됩니다.
관절내 점성보충 디바이스 시장 부문별 분석
관절내 치환술 제품 부문에서는 단회 주사가 예측 기간 중 가장 유망한 부문으로 부상할 것으로 예상됩니다.
단 1회 주사 비스코스 보충제 치료 제품은 비교적 새롭고, 기존의 3-5회 주사 비스코스 보충제 치료 제품에 비해 비용 효율성이 높기 때문입니다. 예를 들어 한 연구에 따르면 안정화 히알루론산 1회 주사로 치료받은 환자는 표준 히알루론산 5회 주사를 맞은 환자에 비해 통계적으로 유의미한 개선 효과를 보였다고 합니다.
또한 무릎 OA 치료에 1회 주사제 사용을 지지하는 연구 결과도 있으며, 의료 시스템에 미치는 경제적 영향도 어느 정도 개선된 것으로 나타났습니다.
또한 주요 기업이 첨단 제품을 개발하고 시장 지위를 유지하기 위해 제품 포트폴리오를 개선하기 위해 투자를 늘리고 있는 것도 관절내 점성보충 디바이스 시장의 성장을 가속하는 요인으로 작용하고 있습니다. 예를 들어 2019년 3월 Seikagaku는 이탈리아에서 무릎 관절염 치료를 위한 관절내 단일 주사 비스코스 보충제인 HyLink®를 출시했습니다.
따라서 위의 요인들이 단일 주사 비스코스 보충제에 대한 수요를 촉진하여 2024-2030년의 예측 기간 중 관절내 대체 요법 장비 시장의 성장에 기여할 가능성이 높습니다.
세계의 관절내 점성보충 디바이스 시장에 대해 조사분석했으며, 시장 규모와 예측, 촉진요인과 과제, 기업과 제품 개요 등을 제공하고 있습니다.
The viscosupplementation Devices Market By Product Type (Single Injection, Three Injections, and Five Injections), End-User (Hospitals, Orthopedic Clinics, and Others), and Geography is projected to grow at a static CAGR forecast till 2030 due to the growing prevalence of osteoarthritis across the globe and rising demand for non-surgical treatment options for osteoarthritis.
The global viscosupplementation devices market was valued at USD 4.08 billion in 2023, growing at a CAGR of 7.94% during the forecast period from 2024 to 2030, to reach USD 6.43 billion by 2030. The rise in demand for Viscosupplementation Devices is primarily attributed to the rising prevalence of osteoarthritis coupled with the growing old age population, growing demand for non-surgical treatment, increasing advancements in the development of hyaluronic acid-based therapies, and well-defined reimbursement policy for viscosupplements, among others.
Viscosupplementation Devices Market Dynamics:
According to the World Health Organization 2022, worldwide around 528 million people were suffering from osteoarthritis in 2019. As per the same source osteoarthritis contributed to 19 million years lived with disability (YLDs). Osteoarthritis also known as "wear and tear" disease is associated with symptoms such as extreme pain, swelling, and others caused by the wearing down of cartilage within the joints.
Moreover, according to the Australian Institute of Health and Welfare 2020 report, between the years 2017 to 2018, one in eleven Australians have osteoarthritis which makes approximately 2.2 million people in the nation.
Therefore, rising osteoarthritis among the population is likely to surge the global viscosupplementation devices market as these devices help reduce pain and swelling in the arthritic/osteoarthritic joint (most commonly, the knee).
The increasing geriatric population is another factor accelerating the market for viscosupplementation devices market. For instance, according to WHO 2022, it has been expected that, globally by 2030, out of 6 at least 1 person will have his/her age 60 years or above. As per the same source, by 2050, the number of people aged 60 years or above will reach around 2.1 billion. The fact mentioned by the American College of Rheumatology 2021, says that osteoarthritis commonly occurs in the old age population and people aged 40 or above are most likely to suffer from it.
In April 2019, the US Food & Drug Administration (FDA) granted Fidia Pharma premarket approval for TRILURON(TM), a single-use syringe, prefilled with sodium hyaluronate to provide relief to the pain associated with osteoarthritis for up to six months. Thus, growing product approvals is also projected to boost the global market for the viscosupplementation market.
However, certain factors such as the high cost associated with hyaluronic acid therapy and the lack of efficiency of the viscosupplementation devices are expected to pose a challenge to the viscosupplementation devices market growth.
Viscosupplementation Devices Market Segment Analysis:
Viscosupplementation Devices Market By Product Type (Single Injection, Three Injections, and Five Injections), End-User (Hospitals, Orthopaedic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the viscosupplementation devices product segment, the single injection is expected to emerge as a foremost segment during the forecasted period.
This is because single injection viscosupplementation products are relatively newer and are also cost-effective in comparison to already existing 3-5 injection viscosupplementation products. For instance, as per research studies, a statistically significant improvement was observed for patients treated with a single stabilized hyaluronic acid injection versus those who received standard hyaluronic acid in five injections.
Also, the studies support the use of single injection products in the treatment of knee OA and found a slight improvement in the economic impact on the healthcare system.
Furthermore, rising investments by key players for improving the product portfolio to develop advanced products and to maintain market position is also a driving factor for the segmental growth of the viscosupplementation devices market. For instance, in March 2019, Seikagaku launched HyLink®, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy.
Thus, the above-mentioned factors are likely to propel the demand for single injection viscosupplementation, thereby contributing to the growth of the viscosupplementation devices market during the forecast period from 2024-2030.
North America is expected to dominate the overall Viscosupplementation Devices Market:
Among all the regions, North America is estimated to account for the largest share of the viscosupplementation devices market in the year 2023. Owing to the significance of key growth factors such as the rising prevalence of osteoarthritis, the growing burden of the old age population, sophisticated healthcare infrastructure, the presence of key players in the market, and fast regulatory approval for new products, in the region, the market for viscosupplementation devices is expected to grow during the forecast period 2024-2030.
The increasing patient population suffering from osteoarthritis is the key factor accelerating the growth of the viscosupplementation devices market in the region. The data published by the Centers for Disease Control and Prevention (CDC) 2020 states that approximately 32.5 million US adults are suffering from osteoarthritis.
The growing burden of the geriatric population is further going to increase the demand for viscosupplementation devices in the region. According to the data provided by the World Bank 2022, about 17% of US citizens aged 65 and above in 2021. Also, according to CDC 2022, around 54.1 million US adults were aged 65 or older in 2019. As per the same source, it has been estimated that by 2060, this number will reach up to 94.7 million in the US. As per the Arthritis by the Numbers report published by the Arthritis Foundation 2019, the risk for knee osteoarthritis increases with age and the annual incidence of knee OA is highest between 55 and 64 years old.
Hence, the above-mentioned factors are going to increase the growth of the viscosupplementation devices market in the region.
Viscosupplementation Devices Market Key Players:
Some of the key market players operating in the viscosupplementation devices market include Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Sanofi, Zimmer Biomet, Smith & Nephew, Ferring B.V., Lifecore Biomedical, LLC, LG Chem, Fidia Farmaceutici S.p.A, OrthogenRx, Bioventus, DePuy Synthes (Johnson & Johnson), Vivacy, APTISSEN, KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH and others.
Recent Developmental Activities in the Viscosupplementation Devices Market:
In August 2022, Seikagaku announced the launch of HyLink®, an Intra-Articular Single Injection Viscosupplement for the treatment of knee osteoarthritis in Taiwan.
In January 2022, Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare commercially launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada for the treatment and improvement of joint functionality and pain in patients suffering from degenerative or mechanical arthropathy of the knees.
Key Takeaway from the Viscosupplementation Devices Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the Global Viscosupplementation Devices Market.
Various opportunities available for the other competitor in the Viscosupplementation Devices Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Viscosupplementation Devices market growth in the coming future?
Target Audience who can be benefited from the Viscosupplementation Devices Market Report Study
Viscosupplementation Devices providers
Research organizations and consulting companies
Viscosupplementation Devices-related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in viscosupplementation devices
Various End-users who want to know more about the viscosupplementation devices market and the latest technological developments in the viscosupplementation devices market.
Frequently Asked Questions for Viscosupplementation Devices Market:
Viscosupplementation devices are preparations that have hyaluronic acid filled in an injection, which is administered into the knee joint to relieve pain associated with osteoarthritis.
The global viscosupplementation devices market was valued at USD 4.08 billion in 2023, growing at a CAGR of 7.94% during the forecast period from 2024 to 2030, to reach USD 6.43 billion by 2030.
The major factors driving the demand for viscosupplementation devices are the rising worldwide prevalence of musculoskeletal disorders such as osteoarthritis, the increasing old age population, recent product approvals, and growing demand for non-surgical osteoarthritis treatment, among others.
Some of the key market players operating in the viscosupplementation devices market include Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Sanofi, Zimmer Biomet, Smith & Nephew, Ferring B.V., Lifecore Biomedical, LLC, LG Chem, Fidia Farmaceutici S.p.A, OrthogenRx, Bioventus, DePuy Synthes (Johnson & Johnson), Vivacy, APTISSEN, KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH, and others.
North America is expected to dominate the overall viscosupplementation devices market. This domination is due to the favorable reimbursement scenario, advanced healthcare infrastructure, and developed research & development facilities in the region.